F-Tag 428 Medication Regimen Review Drug Use Problems in Long Term Care Residents and Key Elements to Performing a Dru

1. F-Tag 428 Medication Regimen ReviewDrug Use Problems in Long Term Care Residents and Key Elements to Performing a Drug Regimen Review Robert L. Maher Jr., Pharm.D, BCPS, CGP Assistant Professor of Clinical Pharmacy Duquesne University School of Pharmacy Vice-President of Clinical Services Mission Pharmacy Services October 26th , 2007

2. Timeline for Pharmacy Tags • Reminder: Appendix N Deleted - Effective June 2004 • Effective date/implementation scheduled for DECEMBER 18, 2006

3. Tags Combined • Pharmaceutical Services • New Tag F428 = Old Tags F428, F429, F430 • DRR/MRR

4. F428 - MRRRegulations • The drug regimen of each resident must be reviewed at least once a month by a licensed pharmacist • The pharmacist must report any irregularities to the attending physician and the director of nursing • And,these reports must be acted upon

5. MRR -What does it say currently? • More Frequent Reviews • Weekly Reviews depending on the resident’s condition and the drugs they are taking • High Risk Residents • Drug Therapy With High Potential for Less Severe Adverse Outcomes In Persons Over 65 (AKA: Beers list) • Note • Review by the surveyor is not necessary for drug therapy given the first seven consecutive days upon admission/readmission, unless there is an immediate threat to health and safety

6. MRR -What does it say currently? • The director of nursing and the attending physician are not required to agree with the pharmacist’s report, • Nor are they required to provide a rationale for their acceptance or rejection of the report • They must, however, act upon the report • This may be accomplished by indicating acceptance or rejection of the report and signing their names • The facility is encouraged to provide the medical director with a copy of drug regimen review reports and to involve the medical director in reports that have not been acted upon

7. Prior to F-Tag 428 • The director of nursing and the attending physician are not required to agree with the pharmacist’s report, • Nor are they required to provide a rationale for their acceptance or rejection of the report • They must, however, act upon the report • This may be accomplished by indicating acceptance or rejection of the report and signing their names • The facility is encouraged to provide the medical director with a copy of drug regimen review reports and to involve the medical director in reports that have not been acted upon

8. F428 - MRR • Definition in glossary: • Goal of promoting positive outcomes and minimizing adverse consequences associated with medications; • The review includes the following with medication-related problems and med errors • Identifying • Reporting • Resolving • Done by collaborating with others members of the interdisciplinary team.

9. F428 - MRR • What are these So “things” we’re preventing, identifying, reporting, and resolving…how are MRPs, med errors, and irregularities defined?

10. F428 - MRRMRPs • A Medication-Related Problem (MRP) is: (NOTE HOW SIMILAR THESE ARE TO THE UNNECESSARY MED ‘CATEGORIES’ IN F-TAG 329) • Use of a medication without adequate indication for use • Use of a medication without identifiable evidence that safer alternatives or more clinically appropriate medications have been considered

11. F428 - MRRMRPs • Use of an appropriate medication that is not reaching treatment goals for reasons such as timing or techniques of administration, dosing intervals, etc. • Use of a medication in an excessive dose (including duplicate therapy) or for excessive duration • Presence of an adverse consequence associated with medication(s)

12. F428 - MRRMRPs • Use of a medication without adequate monitoring • Inadequate monitoring of response to med, or • Inadequate response to findings/results • Presence of or risk for medication errors • Presence of a clinical condition that might warrant initiation of medication • Medication interaction - “TOP 10 DIs in LTC”

13. F428 - MRRMed Errors • A medication error isn’t actually defined in document, but NCCMERP definition is: “A medication error is any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer. Such events may be related to professional practice, health care products, procedures, and systems, including prescribing; order communication; product labeling, packaging, and nomenclature; compounding; dispensing; distribution; administration; education; monitoring; and use.”

14. F428 - MRRIrregularities • An irregularity is: “Any event that is inconsistent with usual, proper, accepted, or right approaches to providing pharmaceutical services (as defined by F425), or that impedes or interferes with achieving the intended outcomes of those services.”

15. F428 - MRR • Given those definitions, important to note that document also states: “This guidance is not intended to imply that all adverse consequences related to medications are preventable, but rather to specify that a SYSTEM exists to assure that medication usage is evaluated on an ongoing basis…”

16. F428 - MRRFrequency of Review • Monthly or more frequently, depending on: • the resident’s condition, and • the risks for adverse consequences related to current medications • This sounds alarming, but it is virtually the same as current survey guidelines

17. F428 - MRRWhere to Conduct the Review • Generally within facility because important info may be attainable only by talking to staff, reviewing “paper” chart, observing/speaking with resident • BUT new technology (electronic health records) may permit the PHARMACIST to conduct some components of the review outside of the facility

18. F428 - MRRSources of Information • May include, but are not limited to: • MARs • Prescribers’ orders • Progress, nursing, consultants’ notes • RAI/MDS • Lab reports • Forms/reports reflecting behavioral monitoring and/or changes in condition • QM/QI reports • Attending physician, facility staff • Interviewing, assessing, and/or observing the resident • Ask yourself, how many of these do I use and should I be using more sources or different types of sources than I am now?

19. F428 - MRRMRR Considerations • MRR considers factors, such as: • Has MD/staff documented objective findings, diagnoses, symptoms to support indication? • Has MD/staff identified and acted upon, or should they be notified about, resident’s allergies, potential interactions/averse consequences? • Is dose, frequency, route, duration consistent with resident’s condition, manufacturer’s recommendations, and applicable standards of practice?

20. F428 - MRRMRR Considerations • Has MD/staff documented progress towards or maintenance of the goal(s) for medications therapy? • Has MD/staff obtained and acted upon lab results, diagnostic studies, or other measurements? • Do med errors exist or do circumstances exist that make errors likely to occur?

21. F428 - MRRMRR Considerations • Has MD/staff noted and acted upon possible medication-related causes of recent or persistent changes in the resident’s condition?…think “Geriatric Syndromes” • Anorexia and/or unplanned weight loss, or weight gain • Behavioral changes, unusual behavior patterns • Bowel function changes • Confusion, cognitive decline, worsening of dementia • Dehydration, fluid/electrolyte imbalance • Depression, mood disturbance • Dysphagia, swallowing difficulty • Excessive sedation, insomnia, or sleep disturbance

22. F428 - MRRMRR Considerations • Falls, dizziness, impaired coordination • GI bleeding • Headaches, muscle pain, generalized aching/pain • Rash, pruritis • Seizure activity • Spontaneous or unexplained bleeding, bruising • Unexplained decline in functional status • Urinary retention or incontinence

23. F428 - MRRNotification of Findings • Pharmacist is expected to document either that no irregularity was identified or the nature of the irregularity(ies), if any were identified • If none, pharmacist would include a signed and dated statement to that effect • Different iterations of this requirement throughout the various drafts, but final focus is on the use of the word “report” as a verb rather than a noun

24. F428 - MRRNotification of Findings • Timeliness of notification depends on potential for or presence of serious adverse consequences • Examples include: • Bleeding resident on anticoagulants • Possible allergic reactions to antibiotic • Collaborate with facility to identify the most effective means of notification/documentation • Notification/documentation may be done electronically

25. F428 - MRRNotification of Findings • Pharmacist’s findings are part of clinical record • If not maintained within active clinical record, it must still be maintained within facility and readily available • Find balance between: • Encouraging/facilitating other HC professionals to utilize • Allowing facilities flexibility in determining a consistent location that suits their needs

26. F428 - MRRResponse to Findings • Physician either: • Accepts recommendation and acts, OR • Rejects the recommendation and provides a brief explanation, such as in a dated progress note • “It is not acceptable for a physician to document only that he/she disagrees with the report without providing some basis for disagreeing.” • For those direct care issues that do not require physician intervention, DON or designated nurse can address and document action taken

27. F428 - MRRLack of Action or Rejection • What about when MD does not act upon or rejects MRR report/recommendations and there is the potential for serious harm? • Facility and CP should contact Medical Director, OR • When attending and MD are same, follow established facility procedure to resolve the situation • No specific timeframe provided for when a report that is not acted upon officially becomes delinquent or “not acted upon”

28. F428 - MRRLack of Action or Rejection • What about continuing to document an issue that the physician has disregarded or rejected? • “Pharmacist does not need to document a continuing irregularity each month if it’s deemed to be clinically insignificant or there is evidence of valid clinical reason for rejection” • “In these situations, pharmacist need only reconsider annually whether to report again or make new recommendation.”

29. How to sort through all the MRPs in Long Term care

30. Types of Suboptimal Drug Use 1. Overutilization (polypharmacy) 2. Underutilization 3. Inappropriate utilization Hanlon JT, et al. J Am Geriatr Soc 2001;49:200-9.

31. Total Drug Therapy Cost Control • Total Drug Cost $= (Product Cost + Distribution Cost) x Utilization + Medication Related Problems (Therapeutic Failures + ADRS)

33. Performing MRR • Familiarize with Medicare and Medicaid requirements • Familiarize with recent facility surveys • Familiarize with documentation procedures • Familiarize with lines of communication • Familiarize with Medical and Nursing Staff • Set dates and times for doing MRR

34. Performing MRR • Get to know the following people • ADON, DON, Medical Director, Medical Records • What reports • Infection control • Restraints • Behavioral • QI Meeting to attend • Committee to involve

35. Performing MRR • The Chart • Admission Records • History and Physical Examination • Physician or Prescriber Orders • MARS • Omissions (reasons) • Prn use – frequency – documented effect • Nursing Progress Notes • Hospital Discharge Note - ?? Fax to the pharmacy

36. Performing MRR • The Chart • Nursing Progress Notes • Nursing Staff Communication • Resident Condition • Daily Progress • Treatment Plans • Vital Signs • Monthly Summaries • Monitoring of Outcomes of Therapy • Documentation of Adverse Effects • Functional Ability of Resident • Resident Complaints

37. Performing DRR • The Chart • Physician or Prescriber Progress Notes • Diagnosis, Rationale, Therapeutic Outcomes • Consultant Notes • Psych, Dietary, Social Services, etc.. • DRR Documentation, Justification of Med use • Clinical Lab Data • Urinalysis, Serum Drug Concentration, CBC, Renal Function test, Thyroid Test • Timing of labs

38. Performing MRR • Timing of MRR • Prospective DRR • Upon Admission • Target high risk medications • Concurrent MRR • Retrospective MRR • Discontinued medications – question of why??

39. Performing MRR • DRR Time Requirements • No more than 100 reviews in one day • Industry standard according to open surveys 9 minutes/chart • Factors to consider • The complexity of MRR • Number of Chronic Conditions • Medical Acuity Level of the Resident • Duration of residency in the facility • Chronic Care or postacute care • The pharmacist familiarity with a particular resident

40. Targeting the High Risk Elderly Patient • Specific Medications NTD Renally Cleared Medications Phase I metabolized medications • Class of Medications anticonvulants narcotic analgesics antipsychotics sedative/hypnotics anticholinergics

41. Targeting the High Risk Elderly Patient • Patient’s on Beer’s Criteria Drugs • CrCl <50ml/min • Low BMI <22kg/m2 • >6 chronic active medical conditions • Polypharmacy > 9 or more chronic meds

42. Targeting the High Risk Elderly Patient • Prior history of an adverse drug reaction • Advanced age (>85) • Those with a history of non-compliance • Those recently discharged from the hospital • Those with certain illness (e.g. dementia)

43. Preventing ADRs in the Elderly • 28% - 56% or ADEs are preventable • Most ADEs result from errors in order writing • 78% are due to “systems failure” • Improve information systems when ordering meds • Increase patient education • Systematic review of medications • DUE and DUR

44. Principles for Optimizing Drug Use in the Elderly • Consider whether drug therapy is necessary • Promote the use of a small number of drugs to treat common problems • Adjust doses and or/dosage intervals for medications • Establish reasonable therapeutic endpoints and monitor for desired outcome • Monitor for adverse drug reactions • Regularly review the need for chronic medications

45. Chronic Medication Review Steps • Assess whether ADRs are the cause of any symptoms • Match problem list with drug list • If on drug but no match with problem list consider whether drug is necessary • If has a chronic condition and not on a medication consider whether there is an evidence based drug to tx the condition • Assess the monitoring for efficacy/safety/appropriateness of the remaining medications

46. Assessing Prescribing Appropriateness Using the Medication Appropriateness Index • Is there an indication for the drug? • Is the medication effective for this condition? • Is the dosage correct? • Are the directions correct? • Are the directions practical? • Are there clinically significant drug-drug interactions? • Are there clinically significant drug-disease interactions? • Is there unnecessary duplications of drugs? • Is the duration of therapy acceptable? • Is this drug on the formulary or the least expensive alternative compared to others of equal utility? • (Hanlon, et al)

47. CMS Guidelines for Monitoring Medication Use DrugMonitoring ACE-I K+ AEDS (older) levels Aminoglycosides Scr, levels Antidiabetics Blood sugar Antipsychotics EPS, TD APAP (>4gm/d) LFTS Appetite stimulants weight, appetite Digoxin Scr, level Diuretic K+ Erythropoiesis stimulants BP, iron, ferritn, CBC Fibrates LFTS, CBC Iron iron, ferritin, CBC Lithium level Niacin blood sugar, LFTs Statins LFTs Theophylline levels Thyroid replacement TFTs Warfarin INR

48. CMS Drug-Drug Interactions Drug EffectedPrecipitantDrug (s) ASA NSAIDs ACE-I K supplements, K sparing diuretics Anticholinergic Anticholinergic Antihypertensives levodopa, nitrates Antiplatelet NSAID CNS med CNS med Digoxin amiodarone, verapamil Lithium ACEI, thiazide diuretics, NSAIDs Meperidine MAOI Phenytoin imidazoles Quinolones Type IA,C, II antiarrhythmics SSRI tramadol, st john wort Sulfonylureas imidazoles Theophylline imidazoles, quinolones, barbiturates Warfarin amiodarone, NSAIDs, sulfonamides, macrolides, quinolones, phenytoin, imidazoles

49. Clinically Important Drug-Disease Interactions Determined by Expert Panel Consensus DrugDisease • Alpha blockers Syncope • Anticholinergics BPH, constipation, dementia, glaucoma (narrow angle) • Aspirin PUD • Barbiturates Dementia • Benzodiazepines Dementia, falls • Bupropion Seizures • CCB 1st generation CHF (systolic dysfunction) • Corticosteroids DM • Digoxin Heart block Lindblad C, Hanlon J et al. Clin Ther 2006 (in press)

50. Clinically Important Drug-Disease Interactions Determined by Expert Panel Consensus DrugDisease • Metoclopramide Parkinson’s disease • Non-aspirin NSAIDs CRF, PUD • Opioid analgesics Constipation • Sedative/hypnotics Falls • Thioridazine Postural hypotension • Tricyclic antidepressants BPH, constipation dementia, falls, heart block postural hypotension • Typical antipsychotics Falls Lindblad C, Hanlon J et al. Clin Ther 2006 (in press)